OTLC — Oncotelic Therapeutics Share Price
0.000.00%
Last trade - 00:00- $11.79m
- $23.91m
- $0.07m
- 20
- 27
- 52
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.18 | ||
| Price to Tang. Book | 2.95 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 199.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.37% | ||
| Return on Equity | -50.92% | ||
| Operating Margin | -10070.73% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 1.74 | n/a | n/a | 0.07 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-β2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.
Directors
- Vuong Trieu CEO (55)
- Amit Shah CFO (53)
- Seymour Fein OTH (71)
- Steven King DRC (55)
- Anthony Maida DRC (67)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 9th, 1992
- Public Since
- August 26th, 1993
- No. of Shareholders
- 79
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 399,684,128
- Address
- 29397 Agoura Road Suite 107, AGOURA HILLS, 91301
- Web
- https://www.oncotelic.com/
- Phone
- +1 6506357000
- Auditors
- Rose, Snyder & Jacobs
Upcoming Events for OTLC
Q3 2024 Oncotelic Therapeutics Inc Earnings Release
Similar to OTLC
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Oncotelic Therapeutics share price?
As of Today at 22:28 UTC, shares in Oncotelic Therapeutics are trading at $0.04. This share price information is delayed by 15 minutes.
How has the Oncotelic Therapeutics share price performed this year?
Shares in Oncotelic Therapeutics last closed at $0.04 and the price had moved by +14.75% over the past 365 days. In terms of relative price strength the Oncotelic Therapeutics share price has underperformed the S&P500 Index by -3.69% over the past year.
What are the analyst and broker recommendations for Oncotelic Therapeutics?
The overall consensus recommendation for Oncotelic Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Oncotelic Therapeutics dividend yield?
Oncotelic Therapeutics does not currently pay a dividend.
Does Oncotelic Therapeutics pay a dividend?
Oncotelic Therapeutics does not currently pay a dividend.
When does Oncotelic Therapeutics next pay dividends?
Oncotelic Therapeutics does not currently pay a dividend.
How do I buy Oncotelic Therapeutics shares?
To buy shares in Oncotelic Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Oncotelic Therapeutics?
As of the previous close price of $0.04, shares in Oncotelic Therapeutics had a market capitalisation of $13.99m.
Where are Oncotelic Therapeutics shares listed?
Here are the trading details for Oncotelic Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: OTLC
What kind of share is Oncotelic Therapeutics?
Based on an overall assessment of its quality, value and momentum Oncotelic Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Oncotelic Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Oncotelic Therapeutics is $4.00. That is 11328.57% above the last closing price of $0.04.
Analysts covering Oncotelic Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the Oncotelic Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncotelic Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -19.25%.
As of the last closing price of $0.04, shares in Oncotelic Therapeutics were trading -5.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Oncotelic Therapeutics PE Ratio?
The Oncotelic Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Oncotelic Therapeutics?
Oncotelic Therapeutics' management team is headed by:
- Vuong Trieu - CEO
- Amit Shah - CFO
- Seymour Fein - OTH
- Steven King - DRC
- Anthony Maida - DRC